

Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi) announced that the disposal of treasury shares (hereinafter, the “disposal”) was completed on July 22, 2022 based on the Board of Directors resolution of June 24, 2022, details of which are provided below. Please see Santen’s release on “Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program” dated June 24, 2022 for more details.

Details

Outline of the disposal

(1)	Type and number of shares to be disposed of	104,654 common shares
(2)	Disposal price	1,034 yen per share
(3)	Total amount of share disposal	108,212,236 yen
(4)	Recipients of allotment of shares to be disposed of, number thereof, and number of shares allotted to be disposed of	3 Directors (excluding outside directors): 52,333 shares 8 Corporate Officers: 52,321 shares
(5)	Disposal date	July 22, 2022

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).